PENTAS Inc.

Based in Japan, PENTAS Inc. specializes in manufacturing advanced medical devices, focusing on innovative treatments for cerebral aneurysms, including the PENTAS Stent and preoperative simulation software. PENTAS Inc. was founded in 2015 in Tokyo, Japan, and is dedicated to the development and manufacturing of medical devices for cerebral aneurysms.

Nour Mohamad serves as the Founder, while Mohamedali vs is the CEO. The company has participated in 2 deals, with the most recent deal occurring on July 31, 2023. PENTAS Inc. specializes in the development and manufacturing of advanced medical devices, primarily focusing on treatments for cerebral aneurysms.

Their core product, the PENTAS Stent, is a metal stent designed specifically for the treatment of brain aneurysms, allowing for safe and precise delivery to the treatment site via a dedicated microcatheter. The company also provides preoperative simulation software that visualizes the placement of the PENTAS Stent, enhancing procedural accuracy. These innovations aim to improve patient quality of life (QOL) by facilitating safer aneurysm treatments, ultimately contributing to better societal and economic outcomes through effective stroke management. PENTAS's primary customers include healthcare providers, such as hospitals and specialized clinics, particularly in Japan, where their products are predominantly utilized, although they may also look to expand into other international markets.

PENTAS Inc. generates revenue through direct sales of its medical devices and software solutions to healthcare institutions. The transactional structure typically involves B2B engagements with hospitals and clinics that purchase the PENTAS Stent and associated products for their medical practices. The company may implement a pricing strategy that involves direct negotiations based on volume and specific institutional needs.

Additionally, PENTAS may enter partnerships with medical professionals to facilitate training and support for using their products effectively. The diverse offerings, particularly the flagship PENTAS Stent and treatment planning software, position the company to capture a significant share of the market for cerebral aneurysm interventions, driving potential revenue growth through their innovative medical solutions. In July 2023, PENTAS Inc. raised an undisclosed amount in venture funding from new investor New Ecosystem for Startups.

The funding will be used to support the spread of the product not only in Japan but also around the world.